JP2011246450A - 抗潰瘍剤組成物 - Google Patents
抗潰瘍剤組成物 Download PDFInfo
- Publication number
- JP2011246450A JP2011246450A JP2011096696A JP2011096696A JP2011246450A JP 2011246450 A JP2011246450 A JP 2011246450A JP 2011096696 A JP2011096696 A JP 2011096696A JP 2011096696 A JP2011096696 A JP 2011096696A JP 2011246450 A JP2011246450 A JP 2011246450A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lactic acid
- acid bacteria
- spore
- ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title description 10
- 239000003699 antiulcer agent Substances 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 16
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 16
- 208000025865 Ulcer Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 231100000397 ulcer Toxicity 0.000 claims abstract description 11
- 239000003907 antipyretic analgesic agent Substances 0.000 claims abstract description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 208000035475 disorder Diseases 0.000 claims abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 41
- 241000894006 Bacteria Species 0.000 claims description 22
- 239000004310 lactic acid Substances 0.000 claims description 20
- 235000014655 lactic acid Nutrition 0.000 claims description 20
- 230000002496 gastric effect Effects 0.000 claims description 15
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 6
- 230000003637 steroidlike Effects 0.000 abstract description 3
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 2
- 241000186660 Lactobacillus Species 0.000 abstract 1
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 230000002623 sporogenic effect Effects 0.000 abstract 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
- 230000006378 damage Effects 0.000 description 13
- 229960000905 indomethacin Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 230000000767 anti-ulcer Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- -1 sazapyrine Chemical compound 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940066544 lactobacillus sporogenes Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】トラネキサム酸と有胞子性乳酸菌を含有し、非ステロイド性解熱鎮痛消炎剤によって引き起こされる胃粘膜障害及び/又は潰瘍の治療剤である医薬組成物。
【選択図】なし
Description
(1):トラネキサム酸及び有胞子性乳酸菌を含有する医薬組成物。
(2):胃粘膜障害治療剤である(1)に記載の医薬組成物。
(3):潰瘍治療剤である(1)に記載の医薬組成物。及び、
(4):非ステロイド性解熱鎮痛消炎剤によって引き起こされる胃粘膜障害及び/又は潰瘍の治療剤である(1)〜(3)のいずれか1に記載の医薬組成物。
(1)被検物質
インドメタシンはSigma-Aldrich製のものを、トラネキサム酸及び有胞子性乳酸菌は第一三共プロファーマ製のものを使用した。
被験物質はメチルセルロース(和光純薬工業製)を注射用水(大塚製薬製)に溶解した0.5%メチルセルロース溶液中に懸濁させて調製した。
Crl:CD雄性ラット5週齢(日本チャールスリバー)を使用した。動物は温度21−27℃、湿度35−75%、照明時間7−19時に制御されたラット飼育室内で個別飼育した。固形試料(オリエンタル酵母工業ラット用固形飼料、CRF-1)及び水道水を自由に摂取させ、1週間予備飼育した後、毛並、体重増加などの一般症状の良好な動物を選別して供試した。
24時間以上絶食したラットに、フレキシブル胃管を装着したディスポーザブルシリンジを用いて、被験物質を経口投与した。なお、被験物質はスターラーを用いて撹拌しながら使用した。
被験薬投与後5時間後に、頚椎脱臼により動物を安楽死させ、速やかに胃を摘出し、内部に生理食塩液を10mL 充填後、2%ホルマリンに浸して翌日まで固定した。固定した胃を大弯に沿って切開し、デジタルノギスを用いて胃粘膜における傷害の長さを測定した。なお、個体の胃粘膜における傷害の長さは、長径を計測し、総和を算出した。
NSAIDs(インドメタシン)の投与による、胃粘膜における傷害の長さの総和(潰瘍長、mm)の結果を表3に示す。表3には、NSAIDsにトラネキサム酸、又は有胞子乳酸菌を各々投与した場合、及び、NSAIDsにトラネキサム酸と有胞子乳酸菌を同時に投与した場合の結果を示した。なお、いずれの投与群も1群9匹であり、潰瘍長(mm)はその平均値で示した。
Claims (4)
- トラネキサム酸及び有胞子性乳酸菌を含有する医薬組成物。
- 胃粘膜障害治療剤である請求項1に記載の医薬組成物。
- 潰瘍治療剤である請求項1に記載の医薬組成物。
- 非ステロイド性解熱鎮痛消炎剤によって引き起こされる胃粘膜障害及び/又は潰瘍の治療剤である請求項1〜3のいずれか1項に記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011096696A JP5753435B2 (ja) | 2010-04-26 | 2011-04-25 | 抗潰瘍剤組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010101107 | 2010-04-26 | ||
JP2010101107 | 2010-04-26 | ||
JP2011096696A JP5753435B2 (ja) | 2010-04-26 | 2011-04-25 | 抗潰瘍剤組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015022804A Division JP5857143B2 (ja) | 2010-04-26 | 2015-02-09 | 抗潰瘍剤組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011246450A true JP2011246450A (ja) | 2011-12-08 |
JP5753435B2 JP5753435B2 (ja) | 2015-07-22 |
Family
ID=45412174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011096696A Active JP5753435B2 (ja) | 2010-04-26 | 2011-04-25 | 抗潰瘍剤組成物 |
JP2015022804A Active JP5857143B2 (ja) | 2010-04-26 | 2015-02-09 | 抗潰瘍剤組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015022804A Active JP5857143B2 (ja) | 2010-04-26 | 2015-02-09 | 抗潰瘍剤組成物 |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP5753435B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113893238A (zh) * | 2020-07-07 | 2022-01-07 | 温州医科大学 | 乳酸及其盐的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05942A (ja) * | 1991-06-26 | 1993-01-08 | Asahi Chem Ind Co Ltd | トラネキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤 |
JPH07228528A (ja) * | 1994-02-16 | 1995-08-29 | Res Inst For Prod Dev | 水溶性トラネキサム酸亜鉛化合物 |
JPH09154535A (ja) * | 1995-12-07 | 1997-06-17 | Sanwa Kagaku Kenkyusho Co Ltd | 納豆菌含有組成物 |
JP2002234836A (ja) * | 2001-02-13 | 2002-08-23 | Kinji Ishida | ストレス対応皮膚外用剤 |
WO2004032915A1 (ja) * | 2002-10-11 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | 抗インフルエンザウイルス剤 |
JP2005343846A (ja) * | 2004-06-04 | 2005-12-15 | Takeda Chem Ind Ltd | アレルギー性鼻炎予防用医薬組成物 |
JP2007055986A (ja) * | 2005-08-26 | 2007-03-08 | Sankyo Lifetech Co Ltd | 抗アレルギー剤 |
JP5232404B2 (ja) * | 2006-06-07 | 2013-07-10 | 第一三共ヘルスケア株式会社 | 有胞子性乳酸菌含有抗感冒ウイルス又は抗インフルエンザウイルス用組成物 |
-
2011
- 2011-04-25 JP JP2011096696A patent/JP5753435B2/ja active Active
-
2015
- 2015-02-09 JP JP2015022804A patent/JP5857143B2/ja active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113893238A (zh) * | 2020-07-07 | 2022-01-07 | 温州医科大学 | 乳酸及其盐的应用 |
CN113893238B (zh) * | 2020-07-07 | 2024-05-24 | 温州医科大学 | 乳酸及其盐的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP5753435B2 (ja) | 2015-07-22 |
JP2015091884A (ja) | 2015-05-14 |
JP5857143B2 (ja) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Forsyth et al. | Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs | |
JP3667381B2 (ja) | 解熱鎮痛剤 | |
JP2023086960A (ja) | 炭酸ランタンを含有する安定な口腔内速崩壊性錠剤 | |
AU2007275360B2 (en) | Methods and medicaments for administration of ibuprofen | |
Carbone et al. | The safety of ketoprofen in different ages | |
JP2008285434A (ja) | 口腔内速崩壊錠 | |
JP5712249B2 (ja) | ロキソプロフェン含有経口用組成物 | |
JP5857143B2 (ja) | 抗潰瘍剤組成物 | |
Brune et al. | Aspirin and acetaminophen: should they be available over the counter? | |
NZ549661A (en) | Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome | |
CA2918004C (en) | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation | |
JP2007023026A (ja) | イブプロフェン含有経口用医薬組成物 | |
JP7335954B2 (ja) | 白頭翁サポニンb4の抗急性痛風性関節炎の医薬における用途 | |
JP2022169626A (ja) | 皮膚疾患の処置のための併用療法 | |
JP6157214B2 (ja) | 解熱鎮痛薬組成物 | |
JP6334088B2 (ja) | 解熱鎮痛薬組成物 | |
JP2018536690A (ja) | 皮膚障害の治療用医薬製剤、ならびにその製造方法および用法 | |
RU2690372C2 (ru) | Лекарственные средства, содержащие диацереин, и способы снижения уровней мочевой кислоты в крови с его использованием | |
JP6804190B2 (ja) | 医薬組成物 | |
TWI593420B (zh) | 用於減緩關節炎的組合物及其醫藥品、製造方法與應用 | |
UA146735U (uk) | Фармацевтичний препарат для лікування болю та запалення | |
TW202140010A (zh) | 控釋組合物 | |
JP2014098009A (ja) | 経口用イブプロフェン製剤 | |
JP6192405B2 (ja) | ロキソプロフェン含有経口剤組成物 | |
JP2019189558A (ja) | 局所的炎症の抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150209 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150512 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150522 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5753435 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |